Clinical Trial Update: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating upfront use of isatuximab for high-risk AL amyloidosis, sponsored by Emory University. The study status is ACTIVE_NOT_RECRUITI…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Drugs mentioned

• Isatuximab (isatuximab)

Snippet

Sponsor: Emory University | Conditions: AL Amyloidosis | Phase 1 | Status: ACTIVE_NOT_RECRUITING